General practitioners' insight into deprescribing for the multimorbid older individual: A qualitative study

International Journal of Clinical Practice

Volumn 70, Issue 3, 2016, Pages 261-276

  Ailabouni, N J ^a   Nishtala, P S ^a   Mangin, D ^b,c   Tordoff, J M ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CARBONATE; COLECALCIFEROL; DIPYRIDAMOLE; ENALAPRIL; FUROSEMIDE; GLICLAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IPRATROPIUM BROMIDE; MACROGOL; METFORMIN; METOPROLOL; PARACETAMOL; RANITIDINE; SALMETEROL; SIMVASTATIN; SPIRONOLACTONE; TEMAZEPAM;

ARTICLE; AWARENESS; DEPRESCRIPTION; DRUG INDICATION; DRUG MONITORING; EVIDENCE BASED MEDICINE; GENERAL PRACTITIONER; HUMAN; INSOMNIA; NEW ZEALAND; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; QUALITATIVE RESEARCH; TREATMENT PLANNING; AGE; AGED; CLINICAL TRIAL; HEALTH PERSONNEL ATTITUDE; MULTICENTER STUDY; PSYCHOLOGY; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ATTITUDE OF HEALTH PERSONNEL; DEPRESCRIPTIONS; GENERAL PRACTITIONERS; HUMANS; NEW ZEALAND; QUALITATIVE RESEARCH;

EID: 84959372796     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12780     Document Type: Article

References (69)

1. Marengoni A, Angleman S, Melis R, et al., Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev 2011; 10 (4): 430-9.
2. Fuchs Z, Blumstein T, Novikov I, et al., Morbidity, comorbidity, and their association with disability among community-dwelling oldest-old in Israel. J Gerontol A Biol Sci Med Sci 1998; 53 (6): M447-55.
3. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B,. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012; 380 (9836): 37-43.
4. Mangin D, Heath I, Jamoulle M,. Beyond diagnosis: rising to the multimorbidity challenge. BMJ 2012; 344: e3526.
5. Scott IA, Gray LC, Martin JH, Pillans PI, Mitchell CA,. Deciding when to stop: towards evidence-based deprescribing of drugs in older populations. Evid Based Med 2013; 18 (4): 121-4.
6. Gnjidic D, Hilmer SN, Blyth FM, et al., Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 2012; 65 (9): 989-95.
7. Ni Chroinin D, Ni Chroinin C, Beveridge A,. Factors influencing deprescribing habits among geriatricians. Age Ageing 2015; 44 (4): 704-8.
8. Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD,. The benefits and harms of deprescribing. Med J Aust 2014; 201: 386-9.
9. Tinetti ME, Han L, Lee DSH, et al., Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med 2014; 174 (4): 588-95.
10. Hilmer SN, Gnjidic D,. The effects of polypharmacy in older adults. Clin Pharmacol Ther 2009; 85 (1): 86-8.
11. Lu WH, Wen YW, Chen LK, Hsiao FY,. Effect of polypharmacy, potentially inappropriate medications and anticholinergic burden on clinical outcomes: a retrospective cohort study. Can Med Assoc J 2015; 187 (4): E130-7.
12. Scott IA, Anderson K, Freeman C, Stowasser DA,. First do no harm: a real need to deprescribe in older patients. Med J Aust 2014; 201 (7): 390-2.
13. Thomsen LA, Winterstein AG, Sondergaard B, Haugbolle LS, Melander A,. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother 2007; 41 (9): 1411-26.
14. Gill TM, Robison JT, Tinetti ME,. Predictors of recovery in activities of daily living among disabled older persons living in the community. J Gen Intern Med 1997; 12 (12): 757-62.
15. Mangoni AA, Jackson SH,. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004; 57 (1): 6-14.
16. McLean AJ, Le Couteur DG,. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004; 56 (2): 163-84.
17. Hilmer SN, McLachlan AJ, Le Couteur DG,. Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol 2007; 21 (3): 217-30.
18. Abernethy DR,. Altered pharmacodynamics of cardiovascular drugs and their relation to altered pharmacokinetics in elderly patients. Clin Geriatr Med 1990; 6 (2): 285-92.
19. Abernethy DR, Schwartz JB, Plachetka JR, Todd EL, Egan JM,. Comparison in young and elderly patients of pharmacodynamics and disposition of labetalol in systemic hypertension. Am J Cardiol 1987; 60 (8): 697-702.
20. Reeve E, Gnjidic D, Long J, Hilmer S,. A systematic review of the emerging definition of "deprescribing" with network analysis: implications for future research and clinical practice. BJCP 2015; 80 (6): 1254-1268.
21. Garfinkel D, Mangin D,. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polyphrmacy. Arch Intern Med 2010; 170 (18): 1648-54.
22. Garfinkel D, Zur-Gil S, Ben-Israel J,. The war against polypharmacy: a new cost-effective geriatric-palliative approach for improving drug therapy in disabled elderly people. Isr Med Assoc J 2007; 9 (6): 430-4.
23. Campbell AJ, Robertson MC, Gardner MM, Norton RN, Buchner DM,. Psychotropic medication withdrawal and a home-based exercise program to prevent falls: a randomized, controlled trial. J Am Geriatr Soc 1999; 47 (7): 850-3.
24. Cumming RG, Le Couteur DG,. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs 2003; 17 (11): 825-37.
25. Reeve E, Wiese MD,. Benefits of deprescribing on patients' adherence to medications. Int J Clin Pharm 2014; 36 (1): 26-9.
26. Eckert KA, Shi Z, Taylor AW, Wittert G, Price K, Goldney RD,. Learning from an epidemiological, population-based study on prescribed medicine use in adults. Pharmacoepidemiol Drug Saf 2013; 22 (3): 271-7.
27. Iyer S, Naganathan V, McLachlan AJ, Le Couteur DG,. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging 2008; 25 (12): 1021-31.
28. Nelson MR, Reid CM, Krum H, Muir T, Ryan P, McNeil JJ,. Predictors of normotension on withdrawal of antihypertensive drugs in elderly patients: prospective study in second Australian national blood pressure study cohort. BMJ 2002; 325 (7368): 815.
29. Woodward MC,. Deprescribing: achieving better health outcomes for older people through reducing medications. J Pharm Pract 2003; 4 (33): 323.
30. Beer C, Loh PK, Peng YG, Potter K, Millar A,. A pilot randomized controlled trial of deprescribing. Ther Adv Drug Saf 2011; 2 (2): 37-43.
31. Heath I,. Who needs healthcare-the well or the sick? Br Med J 2005; 330: 954-956.
32. Sackett DL,. The arrogance of preventive medicine. CMAJ 2002; 167 (4): 363-364.
33. Mangin D, Sweeney K, Heath I,. Preventive health care in elderly people needs rethinking. Brit Med J 2007; 335 (7614): 285.
34. Schuling J, Gebben H, Veehof LJ, Haaijer-Ruskamp FM,. Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC Fam Pract 2012; 13: 56.
35. Hennekens CH, Dalen JE,. Aspirin in the treatment and prevention of cardiovascular disease: past and current perspectives and future directions. Am J Med 2013; 126 (5): 373-8.
36. Baigent C, Blackwell L, Collins R, et al., Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373 (9678): 1849-60.
37. Kubesova HM, Weber P, Meluzinova H, Bielakova K, Matejovsky J,. Benefits and pitfalls of cardiovascular medication in seniors. Wien Klin Wochenschr 2013; 125 (15-16): 425-36.
38. Witham MD, Gillespie ND, Struthers AD,. Age is not a significant risk factor for failed trial of beta-blocker therapy in older patients with chronic heart failure. Age Ageing 2004; 33 (5): 467-72.
39. Anthierens S, Tansens A, Petrovic M, Christiaens T,. Qualitative insights into general practitioners views on polypharmacy. BMC Fam Pract 2010; 11: 65.
40. Halkes PH, Van Gijn J, Kappelle LJ, Koudstaal P, Algra A,. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367 (9523): 1665-73.
41. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ,. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol 2008; 51 (1): 37-45.
42. Baigent C, Blackwell L, Emberson J, et al., Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376 (9753): 1670-81.
43. Taylor F, Huffman MD, Macedo AF, et al., Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; 1: CD004816.
44. Holmes HM, Min LC, Yee M, et al., Rationalizing prescribing for older patients with multimorbidity: considering time to benefit. Drugs Aging 2013; 30 (9): 655-66.
45. Holmes HM,. Rational prescribing for patients with a reduced life expectancy. Clin Pharmacol Ther 2009; 85 (1): 103-7.
46. Amarenco P, Labreuche J, Lavallee P, Touboul PJ,. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004; 35 (12): 2902-9.
47. Bang CN, Okin PM,. Statin treatment, new-onset diabetes, and other adverse effects: a systematic review. Curr Cardiol Rep 2014; 16 (3): 461.
48. Compston J, Bowring C, Cooper A, et al., Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 2013; 75 (4): 392-6.
49. Cosman F, Cauley JA, Eastell R, et al., Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? J Clin Endocrinol Metabol 2014; 99 (12): 4546-54.
50. McClung M, Harris ST, Miller PD, et al., Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013; 126 (1): 13-20.
51. Hamid Z, Riggs A, Spencer T, Redman C, Bodenner D,. Vitamin D deficiency in residents of academic long-term care facilities despite having been prescribed vitamin D. J Am Med Dir Assoc 2007; 8 (2): 71-5.
52. Bolland MJ, Avenell A, Baron JA, et al., Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010; 341: c3691.
53. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR,. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011; 342: d2040.
54. Kamel HK,. Underutilization of calcium and vitamin D supplements in an academic long-term care facility. J Am Med Dir Assoc 2004; 5 (2): 98-100.
55. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C,. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000; 15 (6): 1113-8.
56. Chapuy MC, Pamphile R, Paris E, et al., Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 2002; 13 (3): 257-64.
57. Bischoff HA, Stahelin HB, Dick W, et al., Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 2003; 18 (2): 343-51.
58. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al., American gastroenterological association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135 (4): 1383-91, 91.e1-5.
59. Reeve E, Andrews JM, Wiese MD, Hendrix I, Roberts MS, Shakib S,. Feasibility of a patient-centered deprescribing process to reduce inappropriate use of proton pump inhibitors. Ann Pharmacother 2015; 49 (1): 29-38.
60. Maguire A, Hughes C, Cardwell C, O'Reilly D,. Psychotropic medications and the transition into care: a national data linkage study. J Am Geriatr Soc 2013; 61 (2): 215-21.
61. Stevenson DG, Decker SL, Dwyer LL, et al., Antipsychotic and benzodiazepine use among nursing home residents: findings from the 2004 National Nursing Home Survey. Am J Geriatr Psychiatry 2010; 18 (12): 1078-92.
62. Gray SL, LaCroix AZ, Hanlon JT, et al., Benzodiazepine use and physical disability in community-dwelling older adults. J Am Geriatr Soc 2006; 54 (2): 224-30.
63. Hartikainen S, Lonnroos E,. Systematic review: use of sedatives and hypnotics, antidepressants and benzodiazepines in older people significantly increases their risk of falls. Evid Based Med 2010; 15 (2): 59.
64. Olazaran J, Valle D, Serra JA, Cano P, Muniz R,. Psychotropic medications and falls in nursing homes: a cross-sectional study. J Am Med Dir Assoc 2013; 14 (3): 213-7.
65. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE,. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005; 331 (7526): 1169.
66. Tashkin DP, Celli B, Senn S, et al., A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359 (15): 1543-54.
67. Calverley P, Pauwels R, Vestbo J, et al., Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361 (9356): 449-56.
68. Calverley PM, Anderson JA, Celli B, et al., Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356 (8): 775-89.
69. Nannini L, Cates CJ, Lasserson TJ, Poole P,. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; (4): CD003794.